Our Offerings
By Industry By Function
About Us
Our Viewpoint
NEW
 Senior Management Experts Panel Global Consultants Press Releases Blog
Infographics Market Insights Case Studies Illustrations In The Press
Contact Us
The Business Research Company Logo
Reports Store
Top 50 Healthcare Titles
NEW
 Top 50 Non-Healthcare Titles
NEW
 Opportunities And Strategies Reports Aerospace And Defense Agriculture Chemicals Construction
Electrical And Electronics Financial Services Food And Beverages Healthcare Services Hospitality Information Technology Machinery Media
Medical Equipment Metal And Mineral Mining Oil And Gas Paper, Plastics, Rubber, Wood And Textile Pharmaceuticals Professional Services Recreation
Retail And Wholesale Services Social Services Transport Transport Services Utilities Veterinary Healthcare Filter Reports by Trends
NEW
Market Intelligence Platform
About GMM Global Forecast
NEW
 Mega Trends Analysis
Consultancies Corporate Planning & Strategy Academic Financial Services Legal Services
Pricing Methodology Sources FAQ Press Coverage
Customized Research
Find Customers Optimise Your Marketing Mix Evaluate Competitors Identify Market Opportunities Develop Products And Services
Distributor And Partner Research Plan Finances Streamline Your Operations Devise Market Entry Strategy Explore Custom Research Packages
NEW
Continuous Research
Desk Research Research Reports Senior Executive Interviews Consumer Research Market Sizing And Forecasts
Company Information Analytics And Data Visualization Research Automation Web Crawling And Spidering AI-Empowered Research Services
Request Proposal
Oncology Biosimilars Global Market Report 2025
Request Sample Buy Now
Global Oncology Biosimilars Market Report 2025

Report Price : $4490.00

Pages : 250

Format : PDF

Published : January 2025

Delivery Time : 2-3 Business Days

Purchase This Report
Purchase This Report

Oncology Biosimilars Global Market Report 2025

By Drug Type (Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)), By Cancer Type (Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types), By Distribution Type (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

What Is Covered Under Oncology Biosimilars Market?

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy.

The main drug types of oncology biosimilars are monoclonal antibodies, immunomodulators, hematopoietic agents, and granulocyte colony-stimulating factor (G-CSF). Immunomodulators are a class of drugs that primarily target pathways involved in the treatment of multiple myeloma and a few other cancers. The types of cancer treated include breast cancer, colorectal cancer, blood cancer, neutropenia cancer, and non-small cell lung cancer, and the various distribution channels involved are hospital pharmacies, retail pharmacies, and online pharmacies.

Oncology Biosimilars Market 2025 - 2034

What Is The Oncology Biosimilars Market Size 2025 And Growth Rate?

The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2024 to $8.85 billion in 2025 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars.

What Is The Oncology Biosimilars Market Growth Forecast?

The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $16.48 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

How Is The Oncology Biosimilars Market Segmented?

The oncology biosimilars market covered in this report is segmented –

1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)

2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types

3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Monoclonal Antibody: rituximab biosimilars, Trastuzumab Biosimilars, bevacizumab biosimilars, Pembrolizumab Biosimilars

2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars

3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars

4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars

What Is Driving The Oncology Biosimilars Market? Patent Expirations Drive New Oncology Biosimilars

The expiration of the patent of biologics used for the treatment of cancer is driving the production of new oncology biosimilars. Biologics can be patented for a limited period and the expiration of patents for biologics allows the development of new biosimilars. Biologics are targeted drugs synthesized from living organisms that induce the immune system to attack cancer cells. Biosimilars are similar to biologics but are not identical and offer the same effectiveness as biologics at a reduced cost. According to the Center for Biosimilars, patents on nearly 20 oncology biologics will expire by 2023, leading to the development of new biosimilars in cancer care. The increased number of patent expiry is expected to boost the demand for the production of new oncology biosimilars, thus, driving the market growth for the oncology biosimilars market.

What Is Driving The Oncology Biosimilars Market? Government-Led Cancer Reduction Initiatives Catalysts For Oncology Biosimilars Market Growth

Government initiatives for reducing cancer are expected to propel the growth of the oncology biosimilars market going forward. Government initiatives refer to actions, policies, or programs introduced and implemented by government authorities at various levels (local, regional, national, or even international) to address specific issues or achieve particular objectives. These initiatives to reduce cancer can create a favorable environment for the development and adoption of oncology biosimilars by providing financial support, regulatory assistance, and public awareness. For instance, in 2022, according to the National Cancer Institute, a US-based government agency, President Biden announced a reignition of the Cancer Moonshot, highlighting new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The Cancer Moonshot is marshaling resources across the federal government to speed progress in cancer research and lead to improved cancer prevention. Therefore, government initiatives for reducing cancer drive the oncology biosimilars market.

Who Are The Major Players In The Global Oncology Biosimilars Market?

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech

What Are The Key Trends Of The Global Oncology Biosimilars Market? Fostering Innovation Through Research And Development For Oncology Biosimilars

Pharmaceutical companies are increasingly investing in research and development to produce new oncology biosimilars. The companies are exploiting the growth potential of the rising biosimilar market by investing in their research and development (R&D) processes to support the research and production process of new biosimilars. For instance, in May 2022, Biocon Biologics, an India-based biopharmaceutical company, and Viatris Inc., a US-based company that manufactures biosimilars, launched Abevmy (bevacizumab), their third oncology biosimilar, in Canada. Abevmy is a biosimilar to Roche's Avastin (bevacizumab), a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). By inhibiting VEGF, Abevmy helps prevent the formation of new blood vessels that tumors need to grow.

What Are The Key Trends Of The Global Oncology Biosimilars Market? Increasing Focus On Investments To Support The Battle Of Cancer

Major companies operating in oncology biosimilars are investing in cancer drugs to support the battle of cancer. Company investments in oncology biosimilars emerge as a pivotal bridge between quality cancer care and sustainable healthcare solutions. For instance, in March 2023, Pfizer, a US-based pharmaceutical company merged with Seagen and invested $43 billion to battle cancer. This enhances Pfizer’s presence in the field of oncology and battle against cancer, a leading cause of death worldwide.

Need data on a specific region in this market?
Request Customisation

Regional Outlook For The Global Oncology Biosimilars Market

North America was the largest region in the global oncology biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the oncology biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Oncology Biosimilars Market?

The oncology biosimilars market consists of sales of Ogivri, Herzuma, Ontruzant, and Trazimera. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Oncology Biosimilars Industry?

The oncology biosimilars market research report is one of a series of new reports from The Business Research Company that provides oncology biosimilars market statistics, including oncology biosimilars industry global market size, regional shares, competitors with an oncology biosimilars market share, detailed oncology biosimilars market segments, market trends and opportunities, and any further data you may need to thrive in the oncology biosimilars industry. This oncology biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Oncology Biosimilars Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2025 $8.85 billion
Revenue Forecast In 2034 $16.48 billion
Growth Rate CAGR of 16.8% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars
2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars
3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars
4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech
Customization Scope Request for Sample
Pricing And Purchase Options Explore Purchase Options
Market Size Value In 2025 $8.85 billion
Revenue Forecast In 2034 $16.48 billion
Growth Rate CAGR of 16.8% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars
2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars
3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars
4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

2. Oncology Biosimilars Market Characteristics

3. Oncology Biosimilars Market Trends And Strategies

4. Oncology Biosimilars Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Oncology Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Oncology Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Oncology Biosimilars Market Growth Rate Analysis

5.4. Global Oncology Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Oncology Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Oncology Biosimilars Total Addressable Market (TAM)

6. Oncology Biosimilars Market Segmentation

6.1. Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Monoclonal Antibody

Immunomodulators

Hematopoietic Agents

Granulocyte Colony-Stimulating Factor (G-CSF)

6.2. Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Breast Cancer

Colorectal Cancer

Blood Cancer

Neutropenia Cancer

Non-Small Cell Lung Cancer

Other Cancer Types

6.3. Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

6.4. Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Rituximab Biosimilars

Trastuzumab Biosimilars

Bevacizumab Biosimilars

Pembrolizumab Biosimilars

6.5. Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Thalidomide Biosimilars

Lenalidomide Biosimilars

Pomalidomide Biosimilars

6.6. Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Epoetin Biosimilars

Darbepoetin Biosimilars

6.7. Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Filgrastim Biosimilars

Pegfilgrastim Biosimilars

7. Oncology Biosimilars Market Regional And Country Analysis

7.1. Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Oncology Biosimilars Market

8.1. Asia-Pacific Oncology Biosimilars Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Oncology Biosimilars Market

9.1. China Oncology Biosimilars Market Overview

9.2. China Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Oncology Biosimilars Market

10.1. India Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Oncology Biosimilars Market

11.1. Japan Oncology Biosimilars Market Overview

11.2. Japan Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Oncology Biosimilars Market

12.1. Australia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Oncology Biosimilars Market

13.1. Indonesia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Oncology Biosimilars Market

14.1. South Korea Oncology Biosimilars Market Overview

14.2. South Korea Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Oncology Biosimilars Market

15.1. Western Europe Oncology Biosimilars Market Overview

15.2. Western Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Oncology Biosimilars Market

16.1. UK Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Oncology Biosimilars Market

17.1. Germany Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Oncology Biosimilars Market

18.1. France Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Oncology Biosimilars Market

19.1. Italy Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Oncology Biosimilars Market

20.1. Spain Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Oncology Biosimilars Market

21.1. Eastern Europe Oncology Biosimilars Market Overview

21.2. Eastern Europe Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Oncology Biosimilars Market

22.1. Russia Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Oncology Biosimilars Market

23.1. North America Oncology Biosimilars Market Overview

23.2. North America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Oncology Biosimilars Market

24.1. USA Oncology Biosimilars Market Overview

24.2. USA Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Oncology Biosimilars Market

25.1. Canada Oncology Biosimilars Market Overview

25.2. Canada Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Oncology Biosimilars Market

26.1. South America Oncology Biosimilars Market Overview

26.2. South America Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Oncology Biosimilars Market

27.1. Brazil Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Oncology Biosimilars Market

28.1. Middle East Oncology Biosimilars Market Overview

28.2. Middle East Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Oncology Biosimilars Market

29.1. Africa Oncology Biosimilars Market Overview

29.2. Africa Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Oncology Biosimilars Market Competitive Landscape And Company Profiles

30.1. Oncology Biosimilars Market Competitive Landscape

30.2. Oncology Biosimilars Market Company Profiles

30.2.1. Biocon Biologics Limited Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Celltrion Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Dr. Reddy's Laboratories Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Intas Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.5. STADA Arzneimittel AG Overview, Products and Services, Strategy and Financial Analysis

31. Oncology Biosimilars Market Other Major And Innovative Companies

31.1. Pfizer Inc.

31.2. Apotex Inc.

31.3. Teva Pharmaceutical Industries Ltd.

31.4. Sandoz International GmbH

31.5. BIOCAD

31.6. Amgen Inc.

31.7. F. Hoffmann-La Roche

31.8. Baxter International Inc.

31.9. Sanofi SA

31.10. Mylan

31.11. Samsung Bioepis

31.12. Biogen International GmbH

31.13. Merck & Co. Inc.

31.14. Coherus Biosciences

31.15. Eli Lilly and Company

32. Global Oncology Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Oncology Biosimilars Market

34. Recent Developments In The Oncology Biosimilars Market

35. Oncology Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Oncology Biosimilars Market In 2029 - Countries Offering Most New Opportunities

35.2 Oncology Biosimilars Market In 2029 - Segments Offering Most New Opportunities

35.3 Oncology Biosimilars Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Biocon Biologics Limited Financial Performance
  • Table 79: Celltrion Inc. Financial Performance
  • Table 80: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Table 81: Intas Pharmaceuticals Ltd. Financial Performance
  • Table 82: STADA Arzneimittel AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Oncology Biosimilars Market, Sub-Segmentation Of Monoclonal Antibody, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Oncology Biosimilars Market, Sub-Segmentation Of Immunomodulators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Oncology Biosimilars Market, Sub-Segmentation Of Hematopoietic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Oncology Biosimilars Market, Sub-Segmentation Of Granulocyte Colony-Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Oncology Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Oncology Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Oncology Biosimilars Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Oncology Biosimilars Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Oncology Biosimilars Market, Segmentation By Distribution Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Biocon Biologics Limited Financial Performance
  • Figure 79: Celltrion Inc. Financial Performance
  • Figure 80: Dr. Reddy's Laboratories Ltd. Financial Performance
  • Figure 81: Intas Pharmaceuticals Ltd. Financial Performance
  • Figure 82: STADA Arzneimittel AG Financial Performance

Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Read More About Key Market Drivers, Trends, and Forecast for the Global Non-Steroidal Anti-inflammatory Drugs Industry

Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Read More About Outlook for Non-Therapeutic Biomolecules Market: Key Developments and Future Strategies to 2029

Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Read More About Global Pain Management Drugs Market Forecast to Reach $104.19 Billion by 2029, Driven by 5.6% CAGR

Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

Read More About Pericarditis Industry Poised for Rapid Expansion, Projected to Hit $3.37 Billion by 2029

A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

Read More About A 2025 analysis offering size estimates, growth trends and technological innovations in the live cell imaging microscopes market.

A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

Read More About A 2025 market overview covering growth forecasts, treatment landscape, and key stakeholders in the isovaleric acidemia treatment market.

A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

Read More About A dynamic 2025 report outlining growth drivers, pipeline innovations, and key markets in liver cancer therapeutics.

A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Read More About A 2025 analysis tracking API pricing, competitive landscape, and growth strategies in the losartan potassium active pharmaceutical ingredient market.

Pharmaceuticals Global Market Report 2022 – By Type (Pharmaceutical Drugs, Biologics), By Distribution Channel (Supermarkets/Hypermarkets, Convenience Stores, E-Commerce), By Nature (Organic, Conventional) – Market Size,...

View Report

Biosimilars Global Market Report 2025 – By Type (Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others), By Product (Recombinant Non-glycosylated Proteins, Recombin...

View Report

Biosimilar Growth Hormones Global Market Report 2025 – By Route Of Administration (Intravenous, Subcutaneous, Intramuscular, Oral), By Application (Growth Hormone Deficiency, Turner Syndrome, Idiopathic Short Stature, Pr...

View Report

Biosimilar Monoclonal Antibodies Global Market Report 2025 – By Type (Synthetic Chemicals, Biopharmaceuticals, Other Types), By Compound (Infliximab, Rituximab, Abciximab, Trastuzumab, Adalimumab, Bevacizumab), By Applic...

View Report

Biosimilar Therapeutic Peptides Global Market Report 2025 – By Type (Innovative, Generic), By Route Of Administration (Parenteral Route, Transdermal Route, Other Route Of Administrations), By Application (Cancer, Cardiov...

View Report

Biosimilar Hormones Global Market Report 2025 – By Type (Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types), By Application (Research & Biotechnology, Diagno...

View Report

Biosimilar Interleukins Global Market Report 2025 – By Type (IL-17, IL-23, IL-1, IL-5, IL-6), By Application (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease (IBD), Other Applicat...

View Report

Biosimilar Lymphocyte Modulator Global Market Report 2025 – By Drug (Campath-1H, Natalizumab Biosimilar, Efalizumab- A1089-Anti-CD11a Biosimilar, Anti-CD38 Daratumumab Biosimilar, Anti-CS1 Elotuzumab Biosimilar), By Dise...

View Report

Frequently Asked Questions

Oncology biosimilars refer to biologically similar drugs or medications that are physiologically comparable to biological cancer treatments. Infection risk is increased by decreased white blood cell counts, which can be treated as a side effect of cancer therapy. For further insights on the Oncology Biosimilars market, request a sample here

The Oncology Biosimilars market major growth driver - Government-Led Cancer Reduction Initiatives Catalysts For Oncology Biosimilars Market Growth. For further insights on the Oncology Biosimilars market, request a sample here

The Oncology Biosimilars market size has grown strongly in recent years. The oncology biosimilars market size has grown exponentially in recent years. It will grow from $6.9 billion in 2024 to $8.85 billion in 2025 at a compound annual growth rate (CAGR) of 28.3%. The growth in the historic period can be attributed to rising prevalence of cancer, patent expirations of biologic cancer drugs, government support for biosimilars, growing investments in biosimilar development and manufacturing, expanding geographical reach of biosimilars. The oncology biosimilars market size is expected to see rapid growth in the next few years. It will grow to $16.48 billion in 2029 at a compound annual growth rate (CAGR) of 16.8%. The growth in the forecast period can be attributed to expanding oncology biosimilar portfolio, patient-centric care, healthcare cost containment, targeted therapies, expanding pipeline. Major trends in the forecast period include biobetters, oncology biosimilar combinations, supportive care biosimilars, real-world evidence. For further insights on the Oncology Biosimilars market, request a sample here

The oncology biosimilars market covered in this report is segmented –
1) By Drug Type: Monoclonal Antibody, Immunomodulators, Hematopoietic Agents, Granulocyte Colony-Stimulating Factor (G-CSF)
2) By Cancer Type: Breast Cancer, Colorectal Cancer, Blood Cancer, Neutropenia Cancer, Non-Small Cell Lung Cancer, Other Cancer Types
3) By Distribution Type: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
Subsegments:
1) By Monoclonal Antibody: Rituximab Biosimilars, Trastuzumab Biosimilars, Bevacizumab Biosimilars, Pembrolizumab Biosimilars
2) By Immunomodulators: Thalidomide Biosimilars, Lenalidomide Biosimilars, Pomalidomide Biosimilars
3) By Hematopoietic Agents: Epoetin Biosimilars, Darbepoetin Biosimilars
4) By Granulocyte Colony-Stimulating Factor (G-CSF): Filgrastim Biosimilars, Pegfilgrastim Biosimilars For further insights on the Oncology Biosimilars market, request a sample here

North America was the largest region in the global oncology biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the oncology biosimilars market report forecast period. The regions covered in the oncology biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. For further insights on the Oncology Biosimilars market, request a sample here.

Major companies operating in the oncology biosimilars market include Biocon Biologics Limited, Celltrion Inc., Dr. Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., STADA Arzneimittel AG, Pfizer Inc., Apotex Inc., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, BIOCAD, Amgen Inc., F. Hoffmann-La Roche, Sanofi SA, Mylan, Samsung Bioepis, Biogen International GmbH, Merck & Co. Inc., Coherus Biosciences, Eli Lilly and Company, Novartis AG, Viatris Inc., Accord Healthcare Ltd., Zydus Cadila Health Care Limited, Hetero Drugs Limited, Mundipharma International Limited, Mabion SA, Polpharma Biologics, Alvotech, Innovent Biologics, Gan & Lee Pharmaceuticals, Henlius Biotech . For further insights on the Oncology Biosimilars market, request a sample here.

Major trends in the Oncology Biosimilars market include Increasing Focus On Investments To Support The Battle Of Cancer. For further insights on the Oncology Biosimilars market, request a sample here.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us
Global Oncology Biosimilars Market Report 2025

Wait, we have a special offer for you! ✋

Get your exclusive 20% discount only on the Global Market Reports now using the code ONLINE20*

YES, get the discount! No, I'd pay the full price

*Copy paste the discount code in the cart

Back to top